<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160351</url>
  </required_header>
  <id_info>
    <org_study_id>HS/CTP/HD/001</org_study_id>
    <nct_id>NCT04160351</nct_id>
  </id_info>
  <brief_title>A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Medium Cut-Off Membrane Dialyser Compared With High Flux Dialyser Among Patients With Chronic Haemodialysis</brief_title>
  <acronym>HD-1</acronym>
  <official_title>A Randomised, Open-Label, Cross Over Group, Single-Centre Controlled Study To Evaluate The Clinical Performance Of Medium Cut-Off Membrane Dialyser Compared With High Flux Dialyser In Removing Beta-2- Microglobulin Among Patients With End-Stage Kidney Disease On Chronic Haemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Selayang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Selayang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, cross-over group, single-centre randomised controlled trial comparing
      Medium Cut Off Dialyser with High Flux Dialyser in patients with end-stage renal disease on
      chronic haemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, cross-over group, single-centre randomised controlled trial comparing
      Medium Cut Off(MCO) Dialyser with High Flux Dialyser in patients with end-stage renal disease
      on chronic haemodialysis.

      Patients who are initially on High Flux Dialyser will be randomised into either MCO Dialyser
      (modality A) or High Flux Dialyser (modality B) dialysate. The dialysate flow (QD) and blood
      flow (QB) remains unchanged throughout study period. After 12 treatments (4 weeks) a 4-weeks
      wash-out phase using High-flux dialyzers was performed to minimize carry-over-effects. After
      the 4-weeks washout phase, the modality is switched to the alternative one for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is an open label, cross-over group, single-centre randomised controlled trial comparing MCO Dialyser with High Flux Dialyser in patients with end-stage renal disease on chronic haemodialysis.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Removal of Beta-2-microglobulin</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes to Beta-2-microglobulin level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes to Quality of Life</measure>
    <time_frame>27 weeks</time_frame>
    <description>Changes to Quality of life Using SF-36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory state after intervention</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes to C-Reactive Protein Level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes to Quality of Life</measure>
    <time_frame>27 weeks</time_frame>
    <description>Changes to Quality of life Using EQ-5D-5L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Hemodialysis-Associated Amyloidosis</condition>
  <condition>Dialysis Amyloidosis</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>MCO Dialyser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 treatments (4 weeks) with Medium Cut-Off Dialyzer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Flux Dialyser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 treatments (4 weeks) with High Flux Dialyzer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Theranova 400</intervention_name>
    <description>medium cut-off dialyser</description>
    <arm_group_label>MCO Dialyser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elisio-19H</intervention_name>
    <description>high flux dialyser</description>
    <arm_group_label>High Flux Dialyser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or above

          2. End stage kidney failure receiving hemodialysis for at least 3 years

          3. Currently receiving hemodialysis at our center regularly

          4. Written informed consent

        Exclusion Criteria:

          1. Patients with hemodiafiltration

          2. Catheter-related blood stream infection in the preceding 4 weeks

          3. Malfunctioning of HD catheter

          4. Planned transfer to peritoneal dialysis or transplant within 90 days

          5. Pregnancy

          6. History of active alcohol or substance abuse in the previous 6 months

          7. Concurrent participation in another interventional study

          8. Other medical condition which, in the investigator's judgment, may be associated with
             increased risk to the subject or may interfere with study assessments or outcomes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hin Seng Wong, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ministry of Health, Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Yee Lee, BPharm</last_name>
    <phone>0163208077</phone>
    <email>feiyee7890@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Selayang Hospital</name>
      <address>
        <city>Batu Caves</city>
        <state>Selangor Darul Ehsan</state>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 22, 2019</last_update_submitted>
  <last_update_submitted_qc>November 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemodialysis-Associated Amyloidosis</keyword>
  <keyword>Dialysis Amyloidosis</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

